Search Results

Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”) today reported financial information for the first quarter of 2024, including its cash, cash equivalents and revenues, and provided a corporate update.

Inventiva announced the half-year report of its liquidity contract with Kepler Cheuvreux.

Inventiva announced that two scientific abstracts have been selected for poster presentation at the upcoming International Liver Congress™ 2024 hosted by the European Association for the Study of the Liver on June 5-8, 2024 in Milan, Italy.

Inventiva, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis, also known as non-alcoholic steatohepatitis and other diseases with significant unmet medical needs, announced the nomination of Andre Turenne to its Board of Directors.